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The Charles R. Ream, MD, Award for 
Excellence 2004 
The editorial board of Current Therapeutic Research as selected "Comparison of 
the Effects of Parecoxib and Diclofenac in Preemptive Analgesia: A Prospective, 
Randomized, Assessor-Blind, Single-Dose, Parallel-Group Study in Patients 
Undergoing Elective General Surgery," by Bajaj et al, 1 to receive the fifth annual 
Charles R. Ream, MD, Award for Excellence. This article exemplifies Dr. Ream's 
interest in randomized, controlled trials that try to accomplish important goals. 
Pain and its treatment have been in the general media a great deal in recent 
months. Worries about cyclooxygenase-2 inhibitors and other nonsteroidal 
anti-inflammatory drugs, centering on their toxicity, have been a major con- 
cern. However, analgesic use in preemptive treatment of postsurgical pain and 
decreasing inflammation helps patients avoid some of the worst aspects of sur- 
gery. Unfortunately, physicians often have difficulty treating and preventing pain, 
and investigators have challenges studying it. 
Building on their own previous work showing that intramuscular parecoxib 
provided longer-lasting pain relief than intramuscular diclofenac, 2 these investi- 
gators set out to compare the efficacy and tolerahility of a single, preoperative 
dose of these drugs in patients undergoing ambulatory surgery. The investigators 
took a risk as they chose to use an active drug instead of a placebo as the com- 
parator agent. First, they knew before beginning that their trial would have to 
demonstrate superiority of parecoxib to ensure its acceptance. Second, in study- 
ing preemptive analgesia in a relatively small patient population, they would have 
more difficulty in demonstrating a statistically significant effect. Last, because the 
formulations are distinctive, and thus the code could easily be broken, they had 
to employ a pain assessor who was blinded to treatment assignment. Such a per- 
son can increase study complexity and likelihood of error. 
In this study, the primary end point was the time to use of rescue medication. 
No patient, however, was allowed to receive rescue medication until the 12-hour 
pain assessment had been performed. This long wait for rescue medication, 
coupled with the need for patients to say that their pain was unbearable to re- 
ceive it, raised the bar, perhaps too high. In addition, patients in the diclo- 
fenac group received a second dose at 12 hours. In the absence of the rescue 
measure of effect, the investigators chose to use secondary criteria, mean pain 
intensity score and the percentages of patients achieving various pain relief 
classifications. For both of these end points, the between-treatment differences 
were statistically significant, in favor of parecoxib. 
One or two doses of analgesics rarely result in toxicity. However, in study 
populations containing high-risk patients, myocardial infarction and stroke may 
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have occurred ue to the mechanisms of action of parecoxib-like drugs. In the 
study, parecoxib had little effect, although diclofenac significantly inhibited 
platelet aggregation. 
Given the data that led to the removal of rofecoxib and, most recently, valde- 
coxib, from the US market, toxicity may still occur. The investigators of this 
study were wise to check adenosine diphosphate-induced platelet aggregation. 
Preemptive analgesia is not as common in the United States as it is else- 
where. The article receiving the fifth annual Charles R. Ream, MD, Award for 
Excellence should result in our reexamination f preventive treatment of post- 
operative pain. The authors undertook a challenging clinical trial and carried 
it through with the highest-quality scientific methodology and analysis--all in 
the service of a worthy goal. Dr. Ream would have approved. The investigators 
will receive a crystal globe and the thanks of everyone at the journal and its 
readers for a fine article. 
Michael Weintraub, MD 
Editor Emeritus 
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